PriceTargets.com logo

Ionis Pharmaceuticals - IONS Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $60.65
  • Forecasted Upside: 70.21%
  • Number of Analysts: 19
  • Breakdown:
  • 1 Sell Ratings
  • 5 Hold Ratings
  • 12 Buy Ratings
  • 1 Strong Buy Ratings
$35.63 As of 12/20/2024 06:31 PM ET
▲ +0.04 (0.11%)

This chart shows the closing price for IONS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ionis Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IONS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IONS

Analyst Price Target is $60.65
▲ +70.21% Upside Potential
This price target is based on 19 analysts offering 12 month price targets for Ionis Pharmaceuticals in the last 3 months. The average price target is $60.65, with a high forecast of $77.00 and a low forecast of $37.00. The average price target represents a 70.21% upside from the last price of $35.63.

This chart shows the closing price for IONS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 19 polled investment analysts is to moderate buy stock in Ionis Pharmaceuticals. This rating has held steady since December 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
9/27/2023
  • 1 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 2 sell ratings
Ratings as of
12/26/2023
  • 1 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
3/25/2024
  • 1 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
6/23/2024
  • 2 strong buy ratings
  • 12 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
9/21/2024
  • 1 strong buy ratings
  • 12 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
11/20/2024
  • 1 strong buy ratings
  • 12 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 12 buy ratings
  • 5 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/20/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
12/20/2024William BlairReiterated RatingOutperform
11/14/2024Piper SandlerLower TargetOverweight ➝ Overweight$65.00 ➝ $62.00
11/7/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$82.00 ➝ $77.00
11/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
10/9/2024GuggenheimLower TargetBuy ➝ Buy$70.00 ➝ $65.00
9/26/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$70.00 ➝ $70.00
8/26/2024JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$50.00 ➝ $55.00
8/2/2024GuggenheimBoost TargetBuy ➝ Buy$64.00 ➝ $70.00
8/2/2024The Goldman Sachs GroupBoost TargetSell ➝ Sell$33.00 ➝ $37.00
8/2/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$45.00 ➝ $51.00
8/2/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
8/2/2024BMO Capital MarketsDowngradeOutperform ➝ Market Perform$67.00 ➝ $60.00
7/24/2024Leerink PartnrsUpgradeHold ➝ Strong-Buy
7/24/2024Leerink PartnersUpgradeMarket Perform ➝ Outperform$53.00 ➝ $62.00
7/23/2024TD CowenBoost TargetBuy ➝ Buy$54.00 ➝ $59.00
7/23/2024Bank of AmericaBoost TargetBuy ➝ Buy$67.00 ➝ $68.00
7/22/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
7/16/2024Bank of AmericaBoost TargetBuy ➝ Buy$64.00 ➝ $67.00
7/16/2024Jefferies Financial GroupInitiated CoverageUnderperform ➝ Buy$29.00 ➝ $75.00
6/27/2024Stifel NicolausBoost TargetHold ➝ Hold$50.00 ➝ $53.00
6/14/2024Sanford C. BernsteinUpgradeUnderperform ➝ Market Perform$44.00
6/3/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
5/8/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$85.00 ➝ $82.00
5/8/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$60.00
4/10/2024Wolfe ResearchUpgradePeer Perform ➝ Outperform$58.00
4/9/2024William BlairReiterated RatingOutperform
4/9/2024OppenheimerBoost TargetOutperform ➝ Outperform$72.00 ➝ $75.00
4/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$60.00
3/6/2024OppenheimerBoost TargetOutperform ➝ Outperform$65.00 ➝ $72.00
2/26/2024OppenheimerReiterated RatingOutperform$63.00 ➝ $65.00
2/22/2024Piper SandlerBoost TargetOverweight ➝ Overweight$62.00 ➝ $63.00
2/22/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$60.00
2/1/2024JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$52.00 ➝ $55.00
1/26/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$65.00 ➝ $70.00
1/18/2024Piper SandlerBoost TargetOverweight ➝ Overweight$60.00 ➝ $62.00
1/2/2024Bank of AmericaUpgradeNeutral ➝ Buy$52.00 ➝ $62.00
12/19/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$60.00
12/18/2023Stifel NicolausBoost TargetHold ➝ Hold$45.00 ➝ $50.00
11/17/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$60.00
11/13/2023William BlairReiterated RatingOutperform
11/3/2023The Goldman Sachs GroupBoost TargetSell ➝ Sell$25.00 ➝ $28.00
11/3/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$45.00 ➝ $48.00
10/23/2023Bank of AmericaUpgradeUnderperform ➝ Neutral$33.00 ➝ $52.00
10/5/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$65.00
9/28/2023Raymond JamesInitiated CoverageStrong-Buy$63.00
9/27/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$42.00 ➝ $45.00
9/27/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$60.00
8/10/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$60.00
7/31/2023CitigroupUpgradeNeutral ➝ Buy$36.00 ➝ $60.00
5/4/2023VNET GroupReiterated RatingMaintains
5/4/2023CitigroupUpgradeSell ➝ Neutral$30.00 ➝ $36.00
5/4/2023BarclaysLower Target$40.00 ➝ $37.00
4/11/2023Morgan StanleyBoost TargetEqual Weight$40.00 ➝ $42.00
3/21/2023Sanford C. BernsteinInitiated CoverageUnderperform$31.00
2/23/2023Leerink PartnersLower TargetMarket Perform$34.00 ➝ $27.00
2/23/2023Royal Bank of CanadaReiterated RatingOutperform$65.00
2/23/2023SVB SecuritiesLower Target$34.00 ➝ $27.00
2/23/2023Needham & Company LLCReiterated RatingBuy$60.00
2/23/2023BMO Capital MarketsLower TargetOutperform$70.00 ➝ $67.00
2/23/2023BarclaysLower TargetEqual Weight$44.00 ➝ $40.00
2/3/2023Leerink PartnersBoost TargetMarket Perform$33.00 ➝ $34.00
1/23/2023Leerink PartnersBoost TargetMarket Perform$32.00 ➝ $33.00
1/19/2023Piper SandlerBoost TargetOverweight$60.00 ➝ $62.00
12/21/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$56.00 ➝ $40.00
11/15/2022BarclaysBoost Target$44.00
11/10/2022Morgan StanleyLower TargetOverweight$57.00 ➝ $56.00
11/10/2022Leerink PartnersLower TargetMarket Perform$30.00 ➝ $26.00
11/10/2022CitigroupBoost TargetSell$28.00 ➝ $31.00
11/9/2022Piper SandlerBoost Target$58.00 ➝ $60.00
9/9/2022Morgan StanleyUpgradeUnderweight ➝ Overweight$30.00 ➝ $57.00
8/10/2022CitigroupBoost TargetSell$26.00 ➝ $28.00
7/26/2022Piper SandlerBoost TargetOverweight$55.00 ➝ $58.00
7/18/2022OppenheimerReiterated RatingOutperform$59.00
6/21/2022Leerink PartnersBoost TargetMarket Perform$26.00 ➝ $27.00
6/10/2022Piper SandlerBoost Target$54.00 ➝ $55.00
5/5/2022Stifel NicolausBoost Target$31.00 ➝ $33.00
4/1/2022Leerink PartnersLower TargetMarket Perform$29.00 ➝ $26.00
3/1/2022GuggenheimInitiated CoverageBuy$64.00
2/28/2022CitigroupInitiated CoverageSell$26.00
2/25/2022Leerink PartnersLower TargetMarket Perform$34.00 ➝ $29.00
2/1/2022Bank of AmericaDowngradeBuy ➝ Underperform$40.00 ➝ $30.00
12/17/2021Leerink PartnersLower TargetMarket Perform$36.00 ➝ $34.00
12/14/2021William BlairUpgradeMarket Perform ➝ Outperform
12/10/2021BMO Capital MarketsInitiated CoverageBuy$65.00
12/8/2021Leerink PartnersLower TargetMarket Perform$39.00 ➝ $36.00
11/4/2021Needham & Company LLCLower TargetBuy$84.00 ➝ $60.00
11/4/2021Leerink PartnersBoost TargetMarket Perform$38.00 ➝ $39.00
10/12/2021Morgan StanleyLower TargetUnderweight$33.00 ➝ $31.00
8/19/2021BMO Capital MarketsLower TargetOutperform$70.00 ➝ $68.00
8/5/2021Leerink PartnersLower TargetMarket Perform$41.00 ➝ $38.00
7/16/2021Morgan StanleyLower TargetUnderweight$35.00 ➝ $33.00
5/14/2021Leerink PartnersBoost TargetMarket Perform$36.00 ➝ $41.00
5/7/2021UBS GroupUpgradeSell ➝ Neutral$33.00 ➝ $37.50
5/6/2021Morgan StanleyLower TargetUnderweight$38.00 ➝ $35.00
4/19/2021Morgan StanleyLower TargetUnderweight$43.00 ➝ $38.00
4/5/2021UBS GroupReiterated RatingReduce
3/23/2021BMO Capital MarketsLower TargetPositive ➝ Outperform$90.00 ➝ $76.00
3/23/2021Needham & Company LLCLower TargetBuy$95.00 ➝ $86.00
3/23/2021Leerink PartnersLower TargetMarket Perform$50.00 ➝ $36.00
3/23/2021Morgan StanleyLower TargetUnderweight$50.00 ➝ $43.00
3/23/2021BarclaysLower TargetEqual Weight$52.00 ➝ $47.00
3/23/2021Royal Bank of CanadaLower TargetPositive ➝ Outperform$76.00 ➝ $65.00
3/22/2021Piper SandlerLower TargetNeutral$55.00 ➝ $45.00
3/16/2021UBS GroupReiterated RatingSell$33.00
3/1/2021BarclaysUpgradeUnderweight ➝ Equal Weight$50.00 ➝ $52.00
2/25/2021Morgan StanleyBoost TargetUnderweight$49.00 ➝ $50.00
2/24/2021Piper SandlerLower TargetNeutral$60.00 ➝ $55.00
12/15/2020UBS GroupInitiated CoverageSell$34.00
12/15/2020CowenUpgradeMarket Perform ➝ Outperform
11/5/2020Morgan StanleyLower TargetUnderweight$50.00 ➝ $49.00
11/5/2020Leerink PartnersLower TargetMarket Perform$56.00 ➝ $50.00
10/13/2020Morgan StanleyLower TargetUnderweight$54.00 ➝ $50.00
10/7/2020OppenheimerReiterated RatingBuy$69.00
9/22/2020OppenheimerInitiated CoverageBuy$69.00
9/22/2020Cantor FitzgeraldBoost TargetNeutral$56.00 ➝ $59.00
9/14/2020JPMorgan Chase & Co.Initiated CoverageNeutral
9/8/2020CitigroupLower Target$74.00 ➝ $78.00
9/2/2020BenchmarkInitiated CoverageHold
9/1/2020Royal Bank of CanadaBoost Target$71.00 ➝ $73.00
9/1/2020Leerink PartnersBoost TargetMarket Perform$54.00 ➝ $56.00
9/1/2020OppenheimerLower TargetOutperform$74.00 ➝ $69.00
9/1/2020Needham & Company LLCBoost TargetBuy$89.00 ➝ $91.00
8/30/2020OppenheimerInitiated CoverageBuy$74.00
8/10/2020CitigroupLower TargetBuy$80.00 ➝ $78.00
8/6/2020Morgan StanleyLower TargetUnderweight$56.00 ➝ $54.00
8/6/2020OppenheimerReiterated RatingBuy
8/5/2020Needham & Company LLCInitiated CoverageBuy$89.00
8/5/2020William BlairReiterated RatingHold
7/15/2020Morgan StanleyBoost TargetUnderweight$51.00 ➝ $56.00
7/15/2020Needham & Company LLCReiterated RatingBuy$89.00
6/10/2020William BlairReiterated RatingHold
6/5/2020CitigroupBoost TargetBuy$71.00 ➝ $80.00
5/12/2020Royal Bank of CanadaInitiated CoverageOutperform$71.00
5/7/2020Morgan StanleyBoost TargetUnderweight$48.00 ➝ $51.00
5/7/2020OppenheimerLower TargetOutperform$77.00 ➝ $74.00
5/6/2020Needham & Company LLCReiterated RatingBuy$89.00
4/9/2020CitigroupLower TargetBuy$73.00 ➝ $71.00
3/26/2020Cantor FitzgeraldLower TargetNeutral$65.00 ➝ $56.00
3/9/2020JPMorgan Chase & Co.Boost TargetNeutral$58.00 ➝ $60.00
3/5/2020CitigroupInitiated CoverageBuy$73.00
2/27/2020Piper SandlerLower TargetNeutral$70.00 ➝ $65.00
1/30/2020BMO Capital MarketsReiterated RatingBuy$86.00
1/24/2020William BlairReiterated RatingHold
12/31/2019Bank of AmericaReiterated RatingBuy$70.00
12/23/2019Needham & Company LLCReiterated RatingBuy$87.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.03 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 20 very positive mentions
  • 15 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
5/25/2024
  • 11 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 19 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 16 very positive mentions
  • 15 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 21 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 16 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 11 very positive mentions
  • 21 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 19 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 19 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Ionis Pharmaceuticals logo
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
Read More

Today's Range

Now: $35.63
Low: $35.05
High: $36.40

50 Day Range

MA: $37.44
Low: $33.73
High: $40.36

52 Week Range

Now: $35.63
Low: $33.33
High: $54.44

Volume

4,061,213 shs

Average Volume

1,355,215 shs

Market Capitalization

$5.63 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.35

Frequently Asked Questions

What sell-side analysts currently cover shares of Ionis Pharmaceuticals?

The following equities research analysts have issued research reports on Ionis Pharmaceuticals in the last year: Bank of America Co., Barclays PLC, BMO Capital Markets, Guggenheim, Jefferies Financial Group Inc., JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Royal Bank of Canada, Sanford C. Bernstein, Stifel Nicolaus, StockNews.com, TD Cowen, The Goldman Sachs Group, Inc., Wells Fargo & Company, William Blair, and Wolfe Research.
View the latest analyst ratings for IONS.

What is the current price target for Ionis Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Ionis Pharmaceuticals in the last year. Their average twelve-month price target is $60.65, suggesting a possible upside of 70.2%. Wells Fargo & Company has the highest price target set, predicting IONS will reach $77.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $37.00 for Ionis Pharmaceuticals in the next year.
View the latest price targets for IONS.

What is the current consensus analyst rating for Ionis Pharmaceuticals?

Ionis Pharmaceuticals currently has 1 sell rating, 5 hold ratings, 12 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for IONS.

What other companies compete with Ionis Pharmaceuticals?

Other companies that are similar to Ionis Pharmaceuticals include Biogen, United Therapeutics, Neurocrine Biosciences, Incyte and BioMarin Pharmaceutical. Learn More about companies similar to Ionis Pharmaceuticals.

How do I contact Ionis Pharmaceuticals' investor relations team?

Ionis Pharmaceuticals' physical mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company's listed phone number is (760) 931-9200 and its investor relations email address is [email protected]. The official website for Ionis Pharmaceuticals is www.ionispharma.com. Learn More about contacing Ionis Pharmaceuticals investor relations.